"The expert testified that the standard of care after penile prosthesis surgery is to leave the implant in a semi-inflated state for 4 to 6 weeks, when in fact the standard is to keep the implant in a deflated state," writes Brianne Goodwin, JD, RN.
“It’s actually an exciting time for patients who have metastatic urothelial cancers and prostate cancers or advanced prostate cancers because there are a lot more products on the way, like the newer hormone agents for prostate cancer and the new immunologic agents like PARP inhibitors for different types of cancers," says one urologist.
"If you are self-employed, a solo 401(k) is an excellent option for saving for retirement," writes Jeff Witz, CFP.
"I was overcome by the sinking notion that my career ambitions were regressing from thriving to surviving—a sentiment I know isn’t unique to my training. What may be unique, however, is how my program responded to increasingly evident signs of resident burnout," says James Anaissie, MD.
Experts in treating prostate cancer highlight recent clinical data and discuss practical implications for patient care.
The FDA has approved a supplemental New Drug Application or enzalutamide (XTANDI) for the treatment of patients with metastatic castration-sensitive prostate cancer.
Combining the 4Kscore or ExoDx with multiparametric MRI appears to be the optimal strategy for detecting high-grade prostate cancer, a study from the University of California, San Francisco suggests. However, it is reasonable to consider biomarker testing only in patients who want to avoid biopsy, said first author Claire M. de la Calle, MD.
Clinicians are taught that renal cell carcinoma is radioresistant, but modalities such as stereotactic body radiation therapy (SBRT) can be safe and efficacious in certain patients with RCC. In this interview, Vitaly Margulis, MD, outlines the advantages of SBRT and offers a preview of the RADVAX trial, which combines radiotherapy and immunotherapy.
The Cancer Genome Atlas (TCGA) has provided a “complete genomic roadmap” of muscle-invasive bladder cancer, according to Seth P. Lerner, MD, co-chair of the Analysis Working Group of the TCGA program for muscle-invasive bladder cancer. Dr. Lerner talks to Urology Times about the clinical relevance of the TCGA’s findings, possible implications for upper tract disease, and what further research is needed.
The introduction of targeted therapies and immunotherapies has generated uncertainty regarding the role of the cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma. In this interview, Hyung L. Kim, MD, discusses the recent CARMENA and SURTIME clinical trials, and outlines the upcoming SWOG-1931 trial.